Recent clinical trial results have shown that the drug Glenzoximab developed by Acticor Biotechnology in France can significantly reduce the risk of death in stroke patients. The relevant research was published in the recent Lancet Neurology journal, providing preliminary evidence for the effectiveness of the drug. Stroke, commonly known as "stroke", mainly includes cerebral infarction and cerebral hemorrhage. Professor Charlotte Cordoni è re, Director of the Neurovascular Department at Lille University Hospital in France, said, "There is currently only one method for treating acute ischemic stroke. Due to its limited efficacy, there is an urgent need to find new treatment options." The treatment regimen using Glenzoximab was initially tested in phase I clinical trials in healthy volunteers in 2019, and then in phase Ib/2 clinical trials, patients were tested. Glenzoximab does not increase the risk of bleeding and can directly attack cells that accumulate in the blood, making it very promising in the treatment of stroke. Glenzoximab is only expressed on the surface of platelets and can target glycoprotein VI (GPVI), which is involved in the formation of blood clots. "By specifically binding to the surface of platelets, antibodies prevent them from aggregating on formed blood clots, thereby reducing the risk of blockage," explained Michel Mazzie, a neurologist at the Laribe Waposer Hospital who led the study. 160 patients from Europe have received Glenzoximab as a supplement to standard treatment. The results showed that the mortality rate of patients treated with Glenzoximab was reduced by half compared to the placebo group, from 19% to 8%. Researchers believe that this decrease in mortality rate is related to a significant decrease in intracranial hemorrhage rate. The intracranial hemorrhage rate in patients receiving the new drug decreased to 1.8%, compared to 7.8% in the placebo group. Currently, two Phase III clinical trials are underway. If the progress goes smoothly, the earliest we can see Glenzoximab put into treatment application is 5 years later. (Lai Xin She)